BANK VONTOBEL/PUT/GILEAD SCIENCES/72/0.1/20.09.24 | Delayed Deutsche Boerse AG 13:03:12 05/07/2024 BST | ||
| 0.6 EUR | -1.64% |
|
| Current month | +32.61% | ||
| 1 month | -28.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 0.6 | -1.64% |
| 04/07/24 | 0.61 | +3.39% |
| 03/07/24 | 0.59 | +18.00% |
| 02/07/24 | 0.5 | +8.70% |
| 01/07/24 | 0.46 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update July 05, 2024 at 01:03 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WKN | VM3Q56 |
| ISIN | DE000VM3Q562 |
| Date issued | 09/10/2023 |
| Strike | 72 $ |
| Maturity | 20/09/2024 (77 Days) |
| Parity | 10 : 1 |
| Emission price | 0.56 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.94 € |
|---|---|
| Lowest since issue | 0.152 € |
| Spread | 0.01 € |
| Spread % | 1.61% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
66.59
USD
Average target price
82.97
USD
Spread / Average Target
+24.59%
- Stock Market
- Warrants
- Warrant
